propranolol has been researched along with Endothelioma, Vascular in 21 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Transcatheter arterial embolization combined with propranolol is an effective treatment for life-threatening infantile hepatic hemangioendothelioma." | 7.96 | Infantile hepatic hemangioendothelioma associated with pulmonary artery hypertension and cardiac insufficiency successfully treated with transcatheter arterial embolization and propranolol: A case report. ( Guo, L; Li, J; Song, D; Wang, L; Wu, C; Yin, J, 2020) |
| "A newborn with unresectable kaposiform hemangioendothelioma associated with Kasabach Merritt phenomenon, unresponsive to vincristine and prednisone, received second-line treatment with propranolol at a dose of 2 mg/kg/day, starting at 2 months of life and continued for 13 months." | 7.83 | Successful Propranolol Treatment of a Kaposiform Hemangioendothelioma Apparently Resistant to Propranolol. ( Berti, E; Calvani, M; Defilippi, C; Della Bona, ML; Donzelli, G; Favre, C; Filippi, L; la Marca, G; Perrone, A; Tamburini, A, 2016) |
| "There is currently no consensus on the second-line management of Kaposiform hemangioendothelioma (KHE) that was resistant to prednisolone and vincristine." | 7.81 | Successful treatment of Kaposiform hemangioendothelioma with everolimus. ( Ito, S; Miyazaki, O; Mori, T; Nakazawa, A; Terashima, K; Uno, T, 2015) |
| "Propranolol is a non-selective beta-adrenergic antagonist successfully used in a case of kaposiform hemangioendothelioma (KHE) associated with Kasabach-Merritt phenomenon (KMP)." | 7.78 | Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon. ( Blei, F; Carcao, M; Chiu, YE; Drolet, BA; Fangusaro, J; Kelly, ME; Krol, A; Lofgren, S; Mancini, AJ; Metry, DW; Pope, E; Recht, M; Silverman, RA; Tom, WL, 2012) |
| "A brief comment on efficacy and safety of propranolol in the treatment of parotid hemangioma is presented, with illustration of a typical case." | 7.77 | Comment on efficacy and safety of propranolol in the treatment of parotid hemangioma. ( Zheng, JW, 2011) |
| "Kaposiform hemangioendothelioma is a rare vascular tumor in children." | 5.37 | Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: a new indication for propranolol treatment. ( de Blaauw, I; Hermans, DJ; Kool, LJ; van Beynum, IM; van der Vijver, RJ; van der Vleuten, CJ, 2011) |
| "Consumptive hypothyroidism due to cutaneous hemangioma and hepatic hemangioendothelioma can be managed with propranolol and low-dose sirolimus." | 4.12 | Severe consumptive hypothyroidism in hepatic hemangioendothelioma. ( Dubinski, I; Häberle, B; Küppers, J; Lurz, E; Schmid, I; Schmidt, H; Walther, A, 2022) |
| "Transcatheter arterial embolization combined with propranolol is an effective treatment for life-threatening infantile hepatic hemangioendothelioma." | 3.96 | Infantile hepatic hemangioendothelioma associated with pulmonary artery hypertension and cardiac insufficiency successfully treated with transcatheter arterial embolization and propranolol: A case report. ( Guo, L; Li, J; Song, D; Wang, L; Wu, C; Yin, J, 2020) |
| "Sirolimus is an effective therapy for children with kaposiform hemangioendothelioma with or without the Kasabach-Merritt phenomenon." | 3.88 | ( Dillingham, CS; Givner, LB; McLean, TW; Rinker, EK; Russell, TB, 2018) |
| "A newborn with unresectable kaposiform hemangioendothelioma associated with Kasabach Merritt phenomenon, unresponsive to vincristine and prednisone, received second-line treatment with propranolol at a dose of 2 mg/kg/day, starting at 2 months of life and continued for 13 months." | 3.83 | Successful Propranolol Treatment of a Kaposiform Hemangioendothelioma Apparently Resistant to Propranolol. ( Berti, E; Calvani, M; Defilippi, C; Della Bona, ML; Donzelli, G; Favre, C; Filippi, L; la Marca, G; Perrone, A; Tamburini, A, 2016) |
| "There is currently no consensus on the second-line management of Kaposiform hemangioendothelioma (KHE) that was resistant to prednisolone and vincristine." | 3.81 | Successful treatment of Kaposiform hemangioendothelioma with everolimus. ( Ito, S; Miyazaki, O; Mori, T; Nakazawa, A; Terashima, K; Uno, T, 2015) |
| "Propranolol is a non-selective beta-adrenergic antagonist successfully used in a case of kaposiform hemangioendothelioma (KHE) associated with Kasabach-Merritt phenomenon (KMP)." | 3.78 | Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon. ( Blei, F; Carcao, M; Chiu, YE; Drolet, BA; Fangusaro, J; Kelly, ME; Krol, A; Lofgren, S; Mancini, AJ; Metry, DW; Pope, E; Recht, M; Silverman, RA; Tom, WL, 2012) |
| "A brief comment on efficacy and safety of propranolol in the treatment of parotid hemangioma is presented, with illustration of a typical case." | 3.77 | Comment on efficacy and safety of propranolol in the treatment of parotid hemangioma. ( Zheng, JW, 2011) |
| "The patient has hypoxemia due to abdominal distention during the follow-up period." | 1.46 | Beta blocker and steroid therapy in the treatment of infantile hepatic hemangioendothelioma. ( Bör, Ö; Düzenli Kar, Y; Kebapçı, M; Özdemir, ZC; Şöhret, NC, 2017) |
| "Kaposiform hemangioendothelioma is a rare vascular tumor in children." | 1.37 | Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: a new indication for propranolol treatment. ( de Blaauw, I; Hermans, DJ; Kool, LJ; van Beynum, IM; van der Vijver, RJ; van der Vleuten, CJ, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 17 (80.95) | 24.3611 |
| 2020's | 4 (19.05) | 2.80 |
| Authors | Studies |
|---|---|
| Walther, A | 1 |
| Häberle, B | 1 |
| Küppers, J | 1 |
| Lurz, E | 1 |
| Schmid, I | 1 |
| Schmidt, H | 1 |
| Dubinski, I | 1 |
| Yu, L | 2 |
| Wei, L | 2 |
| Ma, L | 2 |
| Li, L | 2 |
| Wang, L | 1 |
| Song, D | 1 |
| Wu, C | 1 |
| Li, J | 1 |
| Yin, J | 1 |
| Guo, L | 1 |
| Maaloul, I | 1 |
| Aloulou, H | 1 |
| Hentati, Y | 1 |
| Kamoun, T | 1 |
| Mnif, Z | 1 |
| Hachicha, M | 1 |
| Özdemir, ZC | 1 |
| Düzenli Kar, Y | 1 |
| Şöhret, NC | 1 |
| Kebapçı, M | 1 |
| Bör, Ö | 1 |
| Russell, TB | 1 |
| Rinker, EK | 1 |
| Dillingham, CS | 1 |
| Givner, LB | 1 |
| McLean, TW | 1 |
| Emad, A | 1 |
| Fadel, S | 1 |
| El Wakeel, M | 1 |
| Nagy, N | 1 |
| Zamzam, M | 1 |
| Kieran, MW | 1 |
| El Haddad, A | 1 |
| Stiles, JM | 1 |
| Amaya, C | 1 |
| Rains, S | 1 |
| Diaz, D | 1 |
| Pham, R | 1 |
| Battiste, J | 1 |
| Modiano, JF | 1 |
| Kokta, V | 1 |
| Boucheron, LE | 1 |
| Mitchell, DC | 1 |
| Bryan, BA | 1 |
| Tlougan, BE | 1 |
| Lee, MT | 1 |
| Drolet, BA | 2 |
| Frieden, IJ | 1 |
| Adams, DM | 1 |
| Garzon, MC | 1 |
| Wang, Z | 1 |
| Li, K | 1 |
| Dong, K | 1 |
| Xiao, X | 1 |
| Zheng, S | 1 |
| Uno, T | 1 |
| Ito, S | 1 |
| Nakazawa, A | 1 |
| Miyazaki, O | 1 |
| Mori, T | 1 |
| Terashima, K | 1 |
| Korsaga-Somé, N | 1 |
| Maruani, A | 1 |
| Abdo, I | 1 |
| Favrais, G | 1 |
| Lorette, G | 1 |
| Filippi, L | 1 |
| Tamburini, A | 1 |
| Berti, E | 1 |
| Perrone, A | 1 |
| Defilippi, C | 1 |
| Favre, C | 1 |
| Calvani, M | 1 |
| Della Bona, ML | 1 |
| la Marca, G | 1 |
| Donzelli, G | 1 |
| Sarialioglu, F | 1 |
| Erbay, A | 1 |
| Demir, S | 1 |
| Morais, P | 1 |
| Magina, S | 1 |
| Mateus, M | 1 |
| Trindade, E | 1 |
| Jesus, JM | 1 |
| Azevedo, F | 1 |
| Hermans, DJ | 1 |
| van Beynum, IM | 1 |
| van der Vijver, RJ | 1 |
| Kool, LJ | 1 |
| de Blaauw, I | 1 |
| van der Vleuten, CJ | 1 |
| Zheng, JW | 1 |
| Avagyan, S | 1 |
| Klein, M | 1 |
| Kerkar, N | 1 |
| Demattia, A | 1 |
| Blei, F | 3 |
| Lee, S | 1 |
| Rosenberg, HK | 1 |
| Arnon, R | 1 |
| Chiu, YE | 1 |
| Carcao, M | 1 |
| Fangusaro, J | 1 |
| Kelly, ME | 1 |
| Krol, A | 1 |
| Lofgren, S | 1 |
| Mancini, AJ | 1 |
| Metry, DW | 1 |
| Recht, M | 1 |
| Silverman, RA | 1 |
| Tom, WL | 1 |
| Pope, E | 1 |
| Hochman, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sirolimus in the Treatment for Propranolol-resistant Infantile Hepatic Hemangioendothelioma[NCT04406870] | Phase 4 | 36 participants (Anticipated) | Interventional | 2020-07-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for propranolol and Endothelioma, Vascular
| Article | Year |
|---|---|
Medical management of vascular anomalies.
Topics: Adrenergic beta-Antagonists; Hemangioendothelioma; Hemangioma; Humans; Kasabach-Merritt Syndrome; Pr | 2012 |
Management of vascular tumors.
Topics: Adrenergic beta-Antagonists; Child; Granuloma, Pyogenic; Hemangioendothelioma; Hemangioma; Humans; K | 2012 |
19 other studies available for propranolol and Endothelioma, Vascular
| Article | Year |
|---|---|
Severe consumptive hypothyroidism in hepatic hemangioendothelioma.
Topics: Hemangioendothelioma; Humans; Hypothyroidism; Infant; Liver Neoplasms; Male; Propranolol; Sirolimus; | 2022 |
First report of oral atenolol for treatment of kaposiform hemangioendothelioma, a viable alternative to propranolol.
Topics: Atenolol; Hemangioendothelioma; Humans; Kasabach-Merritt Syndrome; Propranolol; Sarcoma, Kaposi | 2023 |
First report of oral atenolol for treatment of kaposiform hemangioendothelioma, a viable alternative to propranolol.
Topics: Atenolol; Hemangioendothelioma; Humans; Kasabach-Merritt Syndrome; Propranolol; Sarcoma, Kaposi | 2023 |
First report of oral atenolol for treatment of kaposiform hemangioendothelioma, a viable alternative to propranolol.
Topics: Atenolol; Hemangioendothelioma; Humans; Kasabach-Merritt Syndrome; Propranolol; Sarcoma, Kaposi | 2023 |
First report of oral atenolol for treatment of kaposiform hemangioendothelioma, a viable alternative to propranolol.
Topics: Atenolol; Hemangioendothelioma; Humans; Kasabach-Merritt Syndrome; Propranolol; Sarcoma, Kaposi | 2023 |
Infantile hepatic hemangioendothelioma associated with pulmonary artery hypertension and cardiac insufficiency successfully treated with transcatheter arterial embolization and propranolol: A case report.
Topics: Antihypertensive Agents; Catheterization; Combined Modality Therapy; Embolization, Therapeutic; Hear | 2020 |
Infantile hepatic hemangioendothelioma successfully treated by low dose of propranolol.
Topics: Dose-Response Relationship, Drug; Female; Hemangioendothelioma; Humans; Infant; Liver Neoplasms; Pro | 2017 |
Beta blocker and steroid therapy in the treatment of infantile hepatic hemangioendothelioma.
Topics: Adrenergic beta-Antagonists; Glucocorticoids; Hemangioendothelioma; Hepatomegaly; Humans; Hypothyroi | 2017 |
Topics: Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Drug Therapy, | 2018 |
Outcome of Children Treated for Infantile Hepatic Hemangioendothelioma.
Topics: Antineoplastic Agents, Hormonal; Combined Modality Therapy; Female; Follow-Up Studies; Hemangioendot | 2020 |
Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma.
Topics: Adrenergic beta-Antagonists; Animals; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Movement | 2013 |
Medical management of tumors associated with Kasabach-Merritt phenomenon: an expert survey.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Data Collection; Hemangioendothelioma; Hemangioma; H | 2013 |
Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon.
Topics: Adrenergic beta-Antagonists; Female; Hemangioendothelioma; Hemangioma; Humans; Kasabach-Merritt Synd | 2014 |
Successful treatment of Kaposiform hemangioendothelioma with everolimus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Drug Resistance, Neoplasm; Everolimus; Hemang | 2015 |
[Kasabach-Merritt phenomenon (KMP) exacerbated by platelet transfusions].
Topics: Aspirin; Axilla; Combined Modality Therapy; Compression Bandages; Disease Progression; Disseminated | 2015 |
Successful Propranolol Treatment of a Kaposiform Hemangioendothelioma Apparently Resistant to Propranolol.
Topics: Drug Resistance, Neoplasm; Hemangioendothelioma; Humans; Infant, Newborn; Infant, Newborn, Diseases; | 2016 |
Response of infantile hepatic hemangioma to propranolol resistant to high-dose methylprednisolone and interferon-α therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Hemangioendothelioma; Hum | 2010 |
Efficacy and safety of propranolol in the treatment of parotid hemangioma.
Topics: Adrenergic beta-Antagonists; Female; Hemangioendothelioma; Hemangioma; Humans; Infant; Liver Neoplas | 2011 |
Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: a new indication for propranolol treatment.
Topics: Adrenergic beta-Antagonists; Antineoplastic Agents, Phytogenic; Disseminated Intravascular Coagulati | 2011 |
Comment on efficacy and safety of propranolol in the treatment of parotid hemangioma.
Topics: Adrenergic beta-Antagonists; Female; Hemangioendothelioma; Hemangioma; Humans; Liver Neoplasms; Neop | 2011 |
Propranolol as a first-line treatment for diffuse infantile hepatic hemangioendothelioma.
Topics: Adrenergic beta-2 Receptor Antagonists; Antineoplastic Agents; Congenital Hypothyroidism; Drug Monit | 2013 |
Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon.
Topics: Adrenergic beta-Antagonists; Child, Preschool; Female; Hemangioendothelioma; Hemangioma; Humans; Inf | 2012 |